Checkpoint Therapeutics, Inc. (CKPT): Earnings growth forecast for next year
International barriers and geopolitics are impacting component procurement for Checkpoint Therapeutics (CKPT), yet laboratories and partners continue to operate without disruption. The consensus forward EPS growth forecast serves as an indicator, where 510.40 expresses the latest level of the metric. Checkpoint Therapeutics (CKPT) relies on creating affordable alternatives to expensive immunotherapies for treating solid tumors in an effort to capture market share.
Analytical breakdowns for Checkpoint Therapeutics
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- company liabilities and liquidity data:
Total Debt to Capital Checkpoint Therapeutics|CKPT - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Checkpoint Therapeutics, Inc.|CKPT - Company Aggregate Debts|Debt to Book Capitalization Ratio Checkpoint Therapeutics|CKPT - Long-Term Liabilities|Company Short-Term Debt Checkpoint Therapeutics|Quick Ratio checkpointtx.com
- earnings and valuation multiples information:
CKPT - Net Financial Result|Expected Profit Checkpoint Therapeutics|CKPT - Price to Earnings Multiple|Projected Price to Earnings Checkpoint Therapeutics|CKPT - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Checkpoint Therapeutics|CKPT - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Checkpoint Therapeutics|CKPT - Earnings per share for the last four quarters|Quarterly EPS earnings growth checkpointtx.com|CKPT - Earnings per share increase in current year|Earnings growth forecast for next year Checkpoint Therapeutics
Basic company analysis:CKPT, Checkpoint Therapeutics, Inc
Since Checkpoint Therapeutics (CKPT) is in the R&D stage without commercial sales, its financial performance is determined exclusively by clinical trial costs. This metric measures the expected change in earnings per share, allowing for an assessment of the fundamental trend relative to speculative noise, which makes the analyst growth estimates chart for EPS a critical tool for identifying high-risk points.
Who Checkpoint Therapeutics competes with
ONC (BeiGene Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Corp HALO|Earnings growth forecast for next year RVMD|Expected earnings per share growth for next year ascentage.com AAPG|Earnings growth forecast for next year CGON (CG Oncology)|Expected earnings per share trend next year URGN|Bicara Bio - Earnings growth forecast for next year|Expected net earnings per share growth next year Personalis Genomics|ERAS: Earnings growth forecast for next year|Expected earnings per share growth for next year delcath.com|Net earnings per share growth forecast for next year Y-mAbs Therapeutics, Inc.|Earnings growth forecast for next year Aura Biosciences Inc|Net earnings per share growth forecast for next year Candel Therapeutics (CADL)|ARAY: Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year SELLAS Life Sciences Group SLS|actuatetherapeutics.com (ACTU) - Expected net earnings per share growth next year|Citius Oncology - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year TuHURA Biosciences, Inc. HURA|Protara (TARA) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year FATE|Expected earnings per share growth for next year WHWK|TCRX (TScan) - Projected earnings per share increase next year|Expected earnings per share growth for next year CSBR (Champions Oncology)|XBIT (xbiotech.com) - Expected earnings per share trend next year|CEL-SCI - Expected earnings per share growth for next year|Projected earnings per share increase next year OSTX (OS Therapies, Inc.)|Radiopharm Theranostics Limited - Earnings growth forecast for next year|Expected earnings per share trend next year ARTV (Artiva Biotherapeutics, Inc.)|ANL: Earnings growth forecast for next year|Expected net earnings per share growth next year Veru Inc (VERU)|Net earnings per share growth forecast for next year Tempest Tx|XLO: Expected earnings per share trend next year|Earnings growth forecast for next year RENB|Earnings growth forecast for next year muraloncology.com (MURA)|Net earnings per share growth forecast for next year Kairos Pharma KAPA|OKUR (OnKure Therapeutics, Inc.) - Net earnings per share change forecast for next year|CytoMed - Earnings growth forecast for next year|Expected net earnings per share growth next year Curis, Inc.|APLM (apollomicsinc.com) - Expected earnings per share growth for next year|tharimmune.com (THAR) - Earnings growth forecast for next year|Expected earnings per share growth for next year ADVB|GNPX (Genprex Inc.) - Projected earnings per share increase next year|Earnings growth forecast for next year CLDI|Consensus forecast of earnings per share growth for next year Sunshine Biopharma Inc.|Earnings growth forecast for next year XBIO (Xenetic Biosciences, Inc.)|SLRX - Expected earnings per share growth for next year|PPBT - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year American Oncology Network AONC|BGNE: Earnings growth forecast for next year|Expected earnings per share growth for next year elevationoncology.com|Net earnings per share growth forecast for next year iCAD Inc.|Earnings growth forecast for next year Ikena|Net earnings per share growth forecast for next year Notable Labs (NTBL)|VIRX: Net earnings per share change forecast for next year|MorphoSys Corp - Expected earnings per share growth for next year|Projected earnings per share increase next year NAYA (NAYA Biosciences Corp)|Ascentage Pharma Group - Earnings growth forecast for next year
